PEOPLE ON THE MOVE
GW Pharmaceuticals
Cannabis-based drug company GW Pharmaceuticals is expanding to the US and has appointed Julian Gangolli as President, North America. CEO Justin Gover has announced he will relocate to the US.
Gangolli was President of Allergan’s North American pharma division between 2004 and April this year.
GW is developing drugs from cannabinoids. Its orphan drug candidate Epidiolex, for childhood epilepsy, is in Phase III trials. Chairman Geoffrey Guy commented, “As Epidiolex nears its final stages of clinical development and as GW prepares for future US launch, the time is right to start building our in-house US commercial infrastructure. Julian’s deep experience at building and running a major US pharmaceutical business built on specialty products will be complemented by the relocation of Justin to the US. with his intimate knowledge of GW, its products and pipeline. Together, they will spearhead GW’s growth in the U.S. and help to bring much needed new treatments to patients.”
The UK-based company will build its American operations in Southern California. Its British headquarters employ 325 staff.
(Image: Bryan William Jones)